中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2009年
24期
10-11
,共2页
非诺贝特%吡格列酮%代谢综合征
非諾貝特%吡格列酮%代謝綜閤徵
비낙패특%필격렬동%대사종합정
Fenofibrate%Pioglitazone%Metabolic syndrome
目的 探讨非诺贝特联合吡格列酮在初诊青少年代谢综合征(MS)治疗中的近期及远期疗效.方法 按国际糖尿病联盟(IDF)关于MS防治建议诊断标准,选择含高血脂、高血糖组分的初诊患者42例,应用非诺贝特联合吡格列酮治疗半年,随访甘油三酯、高密度脂蛋白、空腹血糖、餐后2 h血糖、糖化血红蛋白、腰围、体重指数.结果 血脂、血糖恢复正常患者情况:治疗半年后占90%(38/42),停药半年后占83%(35/42),停药1年后占76%(32/42),漏服药率＜2%.结论 肥胖和胰岛素抵抗是MS的根本危险因素,改善胰岛素敏感性是MS综合治疗措施的基础.非诺贝特联合吡格列酮治疗初诊青少年MS依从性好,近期及远期疗效好,值得推荐为初诊的初始治疗方案.
目的 探討非諾貝特聯閤吡格列酮在初診青少年代謝綜閤徵(MS)治療中的近期及遠期療效.方法 按國際糖尿病聯盟(IDF)關于MS防治建議診斷標準,選擇含高血脂、高血糖組分的初診患者42例,應用非諾貝特聯閤吡格列酮治療半年,隨訪甘油三酯、高密度脂蛋白、空腹血糖、餐後2 h血糖、糖化血紅蛋白、腰圍、體重指數.結果 血脂、血糖恢複正常患者情況:治療半年後佔90%(38/42),停藥半年後佔83%(35/42),停藥1年後佔76%(32/42),漏服藥率＜2%.結論 肥胖和胰島素牴抗是MS的根本危險因素,改善胰島素敏感性是MS綜閤治療措施的基礎.非諾貝特聯閤吡格列酮治療初診青少年MS依從性好,近期及遠期療效好,值得推薦為初診的初始治療方案.
목적 탐토비낙패특연합필격렬동재초진청소년대사종합정(MS)치료중적근기급원기료효.방법 안국제당뇨병련맹(IDF)관우MS방치건의진단표준,선택함고혈지、고혈당조분적초진환자42례,응용비낙패특연합필격렬동치료반년,수방감유삼지、고밀도지단백、공복혈당、찬후2 h혈당、당화혈홍단백、요위、체중지수.결과 혈지、혈당회복정상환자정황:치료반년후점90%(38/42),정약반년후점83%(35/42),정약1년후점76%(32/42),루복약솔＜2%.결론 비반화이도소저항시MS적근본위험인소,개선이도소민감성시MS종합치료조시적기출.비낙패특연합필격렬동치료초진청소년MS의종성호,근기급원기료효호,치득추천위초진적초시치료방안.
Objective To investigate the short and long term curative effect of fenofibrate combined with pioglitazone for the treatment of metabolic syndrome(MS) in adolescences at the preliminary diagnosis.Methods Forty-two patients with hyperlipemia and hyperglycemia at the preliminary diagnosis according to the diagnostic criteria of IDF.Treat with fenofibrate and pioglitazone for 6 months.Follow-up the triglyceride,high density lipoprotein,fasting plasma glucose (FPG),postchallenge plasma glucose two hours(PPG2 h),HbA1c,waist,body mass index(BMI).Results The blood fat and glucose of 90% (38/42) patients return to normal 6 months after treatment,83% (35/42) patients 6 months after drug withdrawal.76% (32/42) patients 12 months after drug withdrawal,missed dose (less than 2%).Conclusions Obesity and insulin resistance(IR) are basic risks factors of MS.Ameliorate the insulin sensitivity is the basic therapeutic measure of MS.The dependence,the short-term and long-term curative effect of fenofibrate combined with pioglitazone for the treatment of MS in adolescences at the preliminary diagnosis are fine.It is worth recommending.
